Skip to content

Study · In vitro (cells) · 2006

1 result

Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist.

Xiang Z, Litherland SA, Sorensen NB, Proneth B, Wood MS, Shaw AM, Millard WJ, Haskell-Luevano C

Biochemistry1 Jun 2006Cited by 117 (Europe PMC)

PMID16752916 (opens in a new tab)DOI10.1021/bi0600300 (opens in a new tab)PepBankPUB-16752916
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    At the S58C and R165Q/W hMC4R variants, MTII potency was reduced only 2-9-fold compared with the wild-type receptor.

    In plain wordsIn cells, MTII lost only 2 to 9 times of its potency at two variant receptors, compared with the normal receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII potency at S58C and R165Q/W hMC4R polymorphisms versus wild type
    Study

    n: not reported in source

    cells expressing 40 human MC4R polymorphic receptors
    Comparator
    Wild-type hMC4R
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Potency reduction vs wild type
    2 to 9 fold
    MTII at S58C and R165Q/W hMC4R

    Source sentences

    Summary
    The S58C and R165Q/W hMC4Rs possessed significantly reduced endogenous agonist potency (15- to 90-fold), but the synthetic ligands NDP-MSH and MTII possessed only 2-9-fold reduced potency as compared to the wild-type receptor, suggesting their potential as therapeutic ligands to treat individuals wi…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.